Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glioma
is a common cancer that affects people worldwide with high morbidity and mortality. Human miR-149 rs2292832 C/T polymorphism and miR-149-5p expressions have been documented to play important roles in various type of cancers. This study aims to assess the impact of miR-149 rs2292832 C/T polymorphism and miR-149-5p expressions in cytotoxic effect of temozolomide against
glioma
cells. A total of 137 cases of
glioma
patients and 21 healthy cases were enrolled in this study for clinical research. We found that miR-149-5p was significantly downregulated in
glioma
cell lines and in blood leukocyte of
glioma
patients. Furthermore, miR-149 rs2292832 C/T polymorphism was significantly associated with
glioma
prognosis and temozolomide resistance. Subsequently, the
glioma
cell lines stable transfected with common miR-149 expression construct (miR-149-T) and the variant miR-149 expression construct (miR-149-C) were used to determine the regulatory effect of miR-149 rs2292832 C on
glioma
cells progression. Data revealed that miR-149 rs2292832 C allele could enhance the miR-149-5p expressions, and therefore, prevent the proliferation of
glioma
cells and increase the cytotoxicity of temozolomide against
glioma
cells. These functions of miR-149-C were demonstrated to be triggered by
CDK6
/SOX2 pathway inhibition. The above results demonstrated that miR-149 rs2292832 C/T polymorphism was a potential prognostic biomarker for
glioma
development by regulating miR-149/
CDK6
axis.
...
PMID:miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells. 3224 54
<< Previous
1
2
3
4
5